Latest Denosumab Stories
Study Shows Adjuvant Prolia Therapy Reduced Fractures by 50 Percent in Postmenopausal Women With Non-Metastatic Breast Cancer THOUSAND OAKS, Calif., June 1, 2015 /PRNewswire/ --
THOUSAND OAKS, Calif., May 13, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data at the 51(st) Annual Meeting of the American Society of Clinical Oncology (ASCO) will showcase the
LONDON, April 2, 2015 /PRNewswire/ -- SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints .
This Approval Provides a New Treatment Option for a Patient Population With High Unmet Medical Need THOUSAND OAKS, Calif., Dec.
Plans to Payout Approximately 60 Percent of Adjusted Net Income on Average to Shareholders Through 2018 NEW YORK, Oct.
Data Presented at the American Society of Bone and Mineral Research 2014 Annual Meeting THOUSAND OAKS, Calif., Sept.
Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016 THOUSAND OAKS, Calif. and BRUSSELS, Sept.
Data Include Eight Year Analyses of Bone Mineral Density Results for Prolia® (Denosumab) and Further Evidence for Significant Bone-Building With Romosozumab THOUSAND OAKS, Calif., Sept.
New Data Reinforces Commitment to Personalized Medicine and Highlights Advances in Immunotherapy Platform THOUSAND OAKS, Calif.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.